{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-028555","form_type":"8-K","ticker":"NAGE","cik":"0001386570","company_name":"Niagen Bioscience, Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.760642+00:00","generated_at":"2026-06-11T21:41:10.260125+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ChromaDex Q2 2023: Net sales $20.3M (+21%), positive Adj EBITDA, raises FY23 guidance to ≥15% growth","bullets":["Net sales $20.3M, up 21% YoY; Tru Niagen sales $16.9M (+16%).","Net loss narrowed to $2.2M ($0.03/sh) from $6.4M ($0.09/sh) a year ago.","Gross margin 60.8% (+80bps); sales & marketing expense improved 1,830 bps to 29.6% of sales.","Positive Adjusted EBITDA of $0.2M vs negative $4.7M in Q2 2022; positive operating cash flows.","Raised FY2023 revenue outlook by 2.5% to at least 15% YoY growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-028555","json":"https://secwatch.observer/filing/0001628280-23-028555.json","markdown":"https://secwatch.observer/filing/0001628280-23-028555.md","text":"https://secwatch.observer/filing/0001628280-23-028555.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1386570/000162828023028555/0001628280-23-028555-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1386570/000162828023028555/cdxc-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:41:10.260125+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c1fd9f4de14e497ad4eb28aef5c87016beed43db","claim":"Niagen Bioscience, Inc. reported the second quarter of 2023 results: revenue $20.3 million, net income $2.2 million, EPS $(0.03) per share. Guidance raised.","evidence_excerpt":"by specific reference in such filing. --- EX-99.1 (EX-99.1) --- ChromaDex Corporation Reports Second Quarter 2023 Financial Results Strong quarter with total net sales of $20.3 million, a gross margin of 60.8% and a net loss of $2.2 million while achieving a positive Adjusted EBITDA of $0.2 million and positive operating cash flows for the three months ended","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828023028555/0001628280-23-028555-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter of 2023"},{"label":"Revenue","value":"$20.3 million"},{"label":"Net income","value":"$2.2 million"},{"label":"EPS","value":"$(0.03) per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}